

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662

Status	RECRUITING
Phase	Phase 2
Sponsor	Immunovant Sciences GmbH
Enrollment	162 participants

Key Eligibility Criteria

Inclusion (3)

- Have met clinical diagnostic criteria for typical CIDP or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP.
- Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline on diagnosis and treatment of CIDP.
- Are currently on, and have been receiving chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (IVIg or SCIg) ± low dose oral corticosteroids for at least 3 months for the treatment of CIDP at the time of the Screening Visit.

Exclusion (13)

- Have current or prior history of IgM paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.
 - Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN/PNS guideline on diagnosis and treatment of CIDP.
 - Have polyneuropathy of causes other than CIDP including but not limited to:
 - Multifocal motor neuropathy
 - Hereditary demyelinating neuropathy
- ... and 8 more (see full listing online)

Locations (135 total)

Site Number - 1612, Tucson, Arizona, United States
Site Number - 1618, Carlsbad, California, United States
Site Number - 1619, Orange, California, United States
... and 132 more locations